APA (7th ed.) Citation

Harada, K., Nakato, K., Yarimizu, J., Yamazaki, M., Morita, M., Takahashi, S., . . . Matsuoka, N. (2012). A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. European journal of pharmacology, 685(1-3), 59-69. https://doi.org/10.1016/j.ejphar.2012.04.013

Chicago Style (17th ed.) Citation

Harada, Katsuya, et al. "A Novel Glycine Transporter-1 (GlyT1) Inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), Improves Cognition in Animal Models of Cognitive Impairment in Schizophrenia and Alzheimer's Disease." European Journal of Pharmacology 685, no. 1-3 (2012): 59-69. https://doi.org/10.1016/j.ejphar.2012.04.013.

MLA (9th ed.) Citation

Harada, Katsuya, et al. "A Novel Glycine Transporter-1 (GlyT1) Inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), Improves Cognition in Animal Models of Cognitive Impairment in Schizophrenia and Alzheimer's Disease." European Journal of Pharmacology, vol. 685, no. 1-3, 2012, pp. 59-69, https://doi.org/10.1016/j.ejphar.2012.04.013.